Search
Thioproperazine
go.drugbank.com/drugs/DB01622ApprovedIt is used for the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes.
Categories: Adrenergic alpha-1 Receptor Antagonists, Dopamine D2 Receptor AntagonistsOpicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigationalOpicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules. … Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily [L2336] and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase
Dimethicone 410
go.drugbank.com/drugs/DB14005Approved[L2162] The name dimethicone has a lot of nomenclature inconsistencies as it is used to refer to common names, generic names, trade names or even for the listing of mixtures. … It is reported that the term dimethicone includes the notation of polydimethylsiloxane and trimethylsiloxy-terminated fluids between 20-30,000 cSt (viscosity).[L2163]
Lindane
go.drugbank.com/drugs/DB00431ApprovedWithdrawnLindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. … In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical
Ublituximab
go.drugbank.com/drugs/DB11850ApprovedInvestigational[L44508] The next year, June 2023, ublituximab was also approved by the EMA for the treatment of relapsing forms of multiple sclerosis in adult patients.[L47486] … [A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012.
Ambrisentan
go.drugbank.com/drugs/DB06403ApprovedInvestigationalAmbrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. … As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.
Categories: Endothelin Receptor AntagonistsBrincidofovir
go.drugbank.com/drugs/DB12151ApprovedInvestigationalThe approval was granted under the agency’s Animal Rule,[L34480] which allows for a drug to be approved based on the results of well-controlled animal studies when human trials would be unethical or infeasible … It is a lipid conjugate pro-drug of the acyclic nucleotide analogue [cidofovir][L34404,A235725] - this lipid conjugate improves drug delivery to the target cells and significantly reduces the nephrotoxicity
Treprostinil
go.drugbank.com/drugs/DB00374ApprovedInvestigationalTreprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. … However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.
Bevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigational[A286054] In 2004, bevacizumab (Avastin) gained FDA approval and became the first antiangiogenic agent introduced to the market, indicated in combination with chemotherapy regimens specific to the type … [A286054] This off-label practice was formalized with the approval of Lytenava (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically
Categories: VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitorsProducts: ABXEDA EAlteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigationalIn the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin. … [A252270] The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting.
Synonyms: t-PA, t-plasminogen activator